Dr. Snowden is an Associate Professor in the Department of Chemistry and Biochemistry. He has research experience in organic synthesis (target directed and methods development/optimization), drug discovery and lead optimization, and physical organic chemistry.  He values collaborative effort wherein experts with competencies in diverse fields work together to address contemporary and prospective therapeutic limitations and to answer questions regarding epigenetic modulation, retroviral replication pathways, or intracellular protein degradation with a focus on pathological processes. (http://snowdengroup.org/)

---

Representative Publications

1. Identification of DOT1L Inhibitors by Structure-Based Virtual Screening Adapted from a Nucleoside-Focused Library, G. S. Gibbons, A. Chakraborty, S. M. Grigsby, A. C. Umeano, C. Liao, O. Moukha-Chafiq,  V. Pathak, B. Mathew, Y.-T. Lee, Y. Dou, S. C. Schürer, R. C. Reynolds, T. S. Snowden, Z. Nikolovska-Coleska. Eur. J. Med. Chem. 119: 112023-112042, 2020.
2. Parallel Solution Phase Synthesis and Preliminary Biological Activity of a 5′-Substituted Cytidine Analog Library, O. Moukha-Chafiq, R. C. Reynolds, J. C. Wilson, T. S. Snowden. ACS Comb. Sci. 21: 628-634, 2019.
3. Small Diversity Library of a-Methyl Amide Analogs of Sulindac for Probing Anticancer Structure-Activity Relationships, B. Mathew, T. S. Snowden, M. C. Connelly, R. K. Guy, R. C. Reynolds. Bioorg. Med. Chem. Lett. 28: 2136-2142, 2018.
4. One-Carbon Homologation of Primary Alcohols and Reductive Homologation of Aldehydes, Z. Li, M. K. Gupta, T. S. Snowden. Eur. J. Org. Chem. 2015: 7009-7019, 2015.
5. Synthesis of Potent CERT Inhibitor HPA-12 Featuring a Tandem Corey-Link and Intramolecular Nucleophilic Acyl Substitution Reaction, J. R. Snider, J. T. Entrekin, T. S. Snowden, D. Dolliver. Synthesis 45: 1899-1903, 2013

Research Interests

The Snowden group is actively engaged in identifying and optimizing drug-like lead compounds and targeted protein degraders with anti-microbial (e.g., HIV-1, HBV, ESKAPE pathogens), anti-inflammatory, or anti-cancer (e.g., protein methyl transferases) activity. In addition, the group has developed organic reactions and strategies that reduce materials costs and greatly improve step economy and reaction yields. Chief among these are operationally simple and inexpensive one-carbon homologations of primary alcohols and aldehydes, including homologations of reactants bearing sensitive chiral centers and multiple functional groups that are incompatible with alternative approaches.